Clifford J Bailey (Clifford Bailey)

Scopus Author ID Scopus Author ID Scopus Author ID Scopus Author ID Scopus Author ID Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Topics

Insulin Resistance

Glycemic Control

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Therapeutic advances in endocrinology and metabolism

Current diabetes reports

This page only lists publications with an associated author ORCID identifier.

Publications

Clifford J Bailey
Metformin: Therapeutic profile in the treatment of type 2 diabetes. Diabetes, obesity & metabolism (2024)
Clifford J Bailey
Diabetes and gout: another role for SGLT2 inhibitors? Therapeutic advances in endocrinology and metabolism 15 (2024)
Clifford J Bailey
Diabetes and gout: another role for SGLT2 inhibitors? Therapeutic advances in endocrinology and metabolism 15 (2024)
Clifford J Bailey
Metformin: Therapeutic profile in the treatment of type 2 diabetes. Diabetes, obesity & metabolism (2024)
Clifford J Bailey, Caroline Day, Srikanth Bellary
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current diabetes reports 22 (1) (2022)
Christophe E M De Block, Clifford J Bailey, Carol H Wysham, Andrea Hemmingway, Sheryl Elaine Allen, Jennifer Peleshok
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes, obesity & metabolism (2022)
Michelle B Paget, Hilary E Murray, Clifford J Bailey, Richard Downing
From insulin injections to islet transplantation: An overview of the journey. Diabetes, obesity & metabolism (2021)
James H Flory, Clifford J Bailey, Catherine M Viscoli
Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care 2020;43:244-246. Diabetes care 43 (10) (2021)
James H Flory, Sean Hennessy, Clifford J Bailey, Catherine M Viscoli
Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes care 43 (1) (2019)
Clifford J Bailey
FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later. Diabetes, obesity & metabolism 21 (5) (2019)
Clifford J Bailey, Stephano Del Prato, Cheryl Wei, Daniel Reyner, Gabriela Saraiva
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes, obesity & metabolism 21 (11) (2019)
Clifford J Bailey, Nikolaus Marx
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. Diabetes, obesity & metabolism 21 (1) (2018)